A method for predicting whether a subject will be eligible to a treatment with an IRE1 RNase inhibitor comprising i) determining the expression levels of ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2, ZNF804A, ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and TMEM255A in a sample obtained from the subject, ii) comparing the expression level of each gene determined a step i) with its respective predetermined reference level and iii) and concluding that the subject will be eligible to a treatment with an inhibitor of IRE1 RNase when the level determined at step i) for ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2 and ZNF804A is lower than the respective predetermined reference level and the level determined at step i) for ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and TMEM255A is higher than its predetermined reference level, or concluding that the subject will be eligible to a treatment with an inhibitor of IRE1 RNase when the level determined at step i) for ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2 and ZNF804A is higher than the respective predetermined reference level and the level determined at step i) for ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and TMEM255A is lower than its predetermined reference level. i) determining the expression levels of ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2, ZNF804A, ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and TMEM255A in a sample obtained from the subject, ii) comparing the expression level of each gene determined a step i) with its respective predetermined reference level and iii) and concluding that the subject will be eligible to a treatment with an inhibitor of IRE1 RNase when the level determined at step i) for ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2 and ZNF804A is lower than the respective predetermined reference level and the level determined at step i) for ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and TMEM255A is higher than its predetermined reference level, or concluding that the subject will be eligible to a treatment with an inhibitor of IRE1 RNase when the level determined at step i) for ASS1, C3, CCL20, COL4A6, CXCL2, CXCL5, CXCL8, IFI44L, IL1B, IL6, KCNN2, MMP1, MMP12, MMP3, PLA2G4A, PPP4R4, SERPINB2, TFPI2 and ZNF804A is higher than the respective predetermined reference level and the level determined at step i) for ANGPT1, CFH, CFI, CLEC3B, COL3A1, COL8A1, DACH1, DCN, FHL1, GAS1, LUM, OXTR, PLAC8, RGS4, TAGLN, TGFB2, THBS1, TIMP3 and TMEM255A is lower than its predetermined reference level. <EOS>